20171221 Financial calendar 2018 EN
Category: 2017
Transgene Announces Upcoming Investor Meetings
20171218 PR financial agenda T1 18
BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors
BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors
Transgene successfully raises € 14.4 million from U.S. and European investors
PR success ABB Transgene
Transgene to Present Additional Immunology Data from the TIME trial with TG4010 in patients with advanced lung cancer at SITC 2017
20171030 PR SITC TG4010
First Patient Treated in a Phase 1/2a Trial (Oncovirac) of Novel Oncolytic Virus TG6002 in Recurrent Glioblastoma
20171026-PR-TG6002
TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B
20171023 PR post AASLD TG1050 final. docx
Third Quarter Marked by Progress in Clinical Development and Research
171019 PR Q3-2017 FINAL
Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B
20171017 PR AASLD TG1050 final
Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC
Caroline Tosch, et al. Journal for ImmunoTherapy of Cancer, 2017, 5:70 – Download the article Publication
